Your health deserves more than guesswork Whether your goal is to finish your first 10K run, dance at your child's wedding, or just live with more energy and less stress, we believe that real success comes from knowing exactly where you're starting from and having a clear, personalized path forward
These injections mirror the GLP-1 hormone to boost insulin release and reduce glucagon secretion, decreasing and controlling blood sugar levels
Product Name KLOW CAS Number 137525-51-0

In the 72-week STEP UP trial, in adults with obesity along with diet and exercise, Wegovy HD (semaglutide) injection 7.2 mg significantly reduced body weight 1 * Analysis of all patients regardless of if they stayed on treatment 7 Co-primary end point: Percent change in body weight 1* Co-primary end point: Reduction in body weight of 5% 1 * Proportion of patients achieving 5% weight loss at 72 weeks * Confirmatory secondary end points (week 72) 1 * 10% weight loss: 79.8% Wegovy HD vs 20.3% placebo 15% weight loss: 63.8% Wegovy HD vs 7.5% placebo 20% weight loss: 45.5% Wegovy HD vs 2.8% placebo ~1 in 3 people (31.2%) of patients achieved 7 * vs 0% of patients with placebo If all patients stayed on treatment 7 20.7% mean weight loss with Wegovy HD vs 2.4% (6 lb) placebo at 72 weeks, in an idealized scenario estimating efficacy if patients remained on treatment for the duration of the trial and used no other weight-loss therapies 7 Mean baseline body weight: Wegovy HD=247.8 lb

We look forward to welcoming you to our Weight Loss Program